Dimerisation increases the immunogenicity of recombinant Parj1/Parj2 allergens

Area of Science:

• Allergen immunotherapy
• Molecular allergology
• Immunology

Background:

• Parietaria allergens (Parj1, Parj2) are implicated in Urticaceae family allergies.
• Recombinant allergens can serve as diagnostic markers and therapeutic agents.
• Preclinical studies assessed the immunogenicity of recombinant Parj1, Parj2, and their isoforms.

Discussion:

• The recombinant hetero-dimeric hybrid derivative (PjED) combines Parj1.0201 and Parj2.
• PjED elicits IgG1 antibody responses that bind multiple Parietaria allergen isoforms.
• This overcomes the limited immunogenicity observed with single monomeric allergens.

Key Insights:

• Recombinant Parj1 and Parj2 allergens share a common IgE binding profile.
• PjED demonstrates superior immunogenicity compared to individual recombinant allergens.
• PjED shows potential for effective treatment of Parietaria allergy.

Outlook:

• Further characterization of PjED for clinical applications in allergy treatment.
• Development of PjED as a therapeutic candidate for Parietaria allergy.
• Exploration of PjED's role in diagnosing and managing allergies induced by the Urticaceae family.